Tuesday January 16th 2018

Goals set after completing a teleconference-delivered program for managing multiple sclerosis fatigue.

This study aimed to describe the focus of goals set by people with MS after a teleconference-delivered fatigue management program and to evaluate the extent to which participants were able to achieve their goals over time. In total, 485 goals were set by 81 participants. Over a follow-up period, 64 participants rated 284 goals regarding progress made toward goal achievement. Approximately 50% of the rated goals were considered achieved. The most common type of goal achieved was that of instrumental activities of daily living. Short-term goals were more likely to be achieved. This study highlights the need for and importance of promoting and teaching goal-setting skills to people with MS. PMID: 25871602 [PubMed – in process] (Source: The American Journal of Occupational Therapy)

View article – 

Goals set after completing a teleconference-delivered program for managing multiple sclerosis fatigue.

Leave a Comment

More from category

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS
FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]

Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.
Effects of sport climbing on multiple sclerosis – Steimer J, Weissert R.

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the central nervous system (CNS) with [Read More]

Researchers use novel PET tracer to assess myelin damage in mouse models of MS
Researchers use novel PET tracer to assess myelin damage in mouse models of MS

The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallmark of the [Read More]

MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe
MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early [Read More]

New PET radiotracer offers insight into multiple sclerosis
New PET radiotracer offers insight into multiple sclerosis

Combining PET scans with a novel radiotracer could help researchers track damage...Read more on AuntMinnie.comRelated [Read More]